American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (986)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (940)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1255)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (311)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (62)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5172)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CD371-targeted CAR T-cells secreting interleukin-18 exhibit robust expansion and disease clearance in patients with refractory acute myeloid leukemia
    Meeting Abstract

    Geyer, M. B.; Dewolf, S.; Mi, X.; Shaffer, B. C.; Cadzin, B.; McAvoy, D.; Hosszu, K. K.; Weis, K.; Lorenc, R.; Lewis, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A real-world analysis of the safety and efficacy of BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma and baseline renal impairment
    Meeting Abstract

    Habib, A.; Ahmed, N.; Khan, A. M.; Chang, D.; Paul, B.; Shaikh, H.; Strouse, C.; Struble, E.; Uegel, A.; Davis, J. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Long-term benefits in patient-reported outcomes and time to next anti-myeloma therapy of ciltacabtagene autoleucel (cilta-cel) versus standard of care for patients with lenalidomide-refractory multiple myeloma: Results from the phase 3 CARTITUDE-4 clinical trial
    Meeting Abstract

    Bar, N.; Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L. O.; Isufi, I.; Harrison, S. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1b study of step-up dosing with ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mian, H.; Baljevic, M.; Magen, H.; Gatt, M. E.; Mazza, I. A.; Searle, E.; Lichtman, E. I.; McKay, J. T.; Plesner, T.; Rodriguez, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Regulatory T cell derived trefoil factor 1 drives thymic regeneration in allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Pierce, J.; Gipson, B.; Serrano-Marin, L.; Argyropoulos, K.; Dewolf, S.; James, S. E.; Kaur, M.; Kousa, A.; Nguyen, C. L.; Rajagopalan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Prognostic impact of measurable residual disease evaluated by next generation flow and PET-CT in clinical practice at Fundación Santa Fe de Bogotá Hospital, Colombia
    Meeting Abstract

    Romero Prieto, M.; Melo Arias, A.; Oros, J. G.; Ovalle, N. T.; Ucros, G.; Galvis, K.; Martinez, D.; Cuellar, G.; Saavedra, C.; Martin, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Initial results from the ASH research collaborative's COVID-19 outcomes in myeloma and the impact of vaccines (COSMIC): A decentralized, real-world evidence study for patients with multiple myeloma to monitor outcomes related to COVID-19 vaccines and infections
    Meeting Abstract

    Usmani, S. Z.; Semmel, E. A.; James, S.; Wood, W. A.; Schroeder, M. A.; Chung, D. J.; Rosenberg, A. S.; Zonder, J. A.; Rubinstein, S. M.; D'Souza, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes of therapies following discontinuation of non-covalent Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia and Richter transformation: Results from an international, multicenter study
    Meeting Abstract

    Thompson, M. C.; Bhat, S. A.; Jurczak, W.; Patel, K.; Shah, N. N.; Woyach, J. A.; Coombs, C. C.; Eyre, T. A.; Danecki, M.; Dlugosz-Danecka, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Enhanced prognostic value of the SKY92 classifier over high-risk cytogenetic aberrations in multiple myeloma: Results from the Prommis real-world study
    Meeting Abstract

    Biran, N.; Dhakal, B.; Niesvizky, R.; Lentzsch, S.; McKay, J.; Vesole, D. H.; Nooka, A. K.; Paul, B.; Hari, P. N.; D'Ambrosi, S.; more...
    Blood (2024)

    Fulltext@MSK | Save